Is PRAX or MLYS more profitable?

Mineralys Therapeutics' return on equity of -27.92% beat Praxis Precision Medicines' return on equity. Company Net Margins Return on Equity Return on Assets Praxis Precision Medicines N/A -43.02% -40.22% Mineralys Therapeutics N/A -27.92% -26.98%

Does the media prefer PRAX or MLYS?

In the previous week, Praxis Precision Medicines and Praxis Precision Medicines both had 8 articles in the media. Mineralys Therapeutics' average media sentiment score of 1.03 beat Praxis Precision Medicines' score of 0.91 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mineralys Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SYRE or MLYS more profitable?

Mineralys Therapeutics' return on equity of -27.92% beat Spyre Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Spyre Therapeutics N/A -42.88% -27.76% Mineralys Therapeutics N/A -27.92% -26.98%

Does the media prefer SYRE or MLYS?

In the previous week, Mineralys Therapeutics had 1 more articles in the media than Spyre Therapeutics. MarketBeat recorded 8 mentions for Mineralys Therapeutics and 7 mentions for Spyre Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.03 beat Spyre Therapeutics' score of 0.85 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mineralys Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CRNX or MLYS?

In the previous week, Mineralys Therapeutics had 1 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 8 mentions for Mineralys Therapeutics and 7 mentions for Crinetics Pharmaceuticals. Mineralys Therapeutics' average media sentiment score of 1.03 beat Crinetics Pharmaceuticals' score of 0.19 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crinetics Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mineralys Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer QGEN or MLYS?

In the previous week, Qiagen had 3 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 11 mentions for Qiagen and 8 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.03 beat Qiagen's score of 0.86 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 6 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mineralys Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MLYS or TGTX?

In the previous week, TG Therapeutics had 11 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 19 mentions for TG Therapeutics and 8 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.03 beat TG Therapeutics' score of 0.48 indicating that Mineralys Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mineralys Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Mineralys Therapeutics (MLYS) Competitors

$27.12 +0.05 (+0.17%)

As of 09:46 AM Eastern

Compare

MLYS vs. PRAX, SYRE, CRNX, QGEN, and TGTX

Should you buy Mineralys Therapeutics stock or one of its competitors? MarketBeat compares Mineralys Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mineralys Therapeutics include Praxis Precision Medicines (PRAX), Spyre Therapeutics (SYRE), Crinetics Pharmaceuticals (CRNX), Qiagen (QGEN), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry.

How does Mineralys Therapeutics compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Mineralys Therapeutics (NASDAQ:MLYS) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

Mineralys Therapeutics' return on equity of -27.92% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-43.02%	-40.22%
Mineralys Therapeutics	N/A	-27.92%	-26.98%

In the previous week, Praxis Precision Medicines and Praxis Precision Medicines both had 8 articles in the media. Mineralys Therapeutics' average media sentiment score of 1.03 beat Praxis Precision Medicines' score of 0.91 indicating that Mineralys Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mineralys Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mineralys Therapeutics has lower revenue, but higher earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	1,004.98	-$303.27M	-$13.37	N/A
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A

67.8% of Praxis Precision Medicines shares are owned by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 3.0% of Praxis Precision Medicines shares are owned by company insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Praxis Precision Medicines currently has a consensus target price of $563.50, suggesting a potential upside of 82.84%. Mineralys Therapeutics has a consensus target price of $49.33, suggesting a potential upside of 82.18%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, equities research analysts plainly believe Praxis Precision Medicines is more favorable than Mineralys Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	4 Strong Buy rating(s)	2.95
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Praxis Precision Medicines has a beta of 2.74, indicating that its share price is 174% more volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market.

Summary

Mineralys Therapeutics beats Praxis Precision Medicines on 8 of the 14 factors compared between the two stocks.

How does Mineralys Therapeutics compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Mineralys Therapeutics (NASDAQ:MLYS) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

Spyre Therapeutics presently has a consensus target price of $101.42, suggesting a potential upside of 7.75%. Mineralys Therapeutics has a consensus target price of $49.33, suggesting a potential upside of 82.18%. Given Mineralys Therapeutics' higher probable upside, analysts clearly believe Mineralys Therapeutics is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Mineralys Therapeutics had 1 more articles in the media than Spyre Therapeutics. MarketBeat recorded 8 mentions for Mineralys Therapeutics and 7 mentions for Spyre Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.03 beat Spyre Therapeutics' score of 0.85 indicating that Mineralys Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mineralys Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mineralys Therapeutics' return on equity of -27.92% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Mineralys Therapeutics	N/A	-27.92%	-26.98%

80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Spyre Therapeutics has a beta of 3.02, indicating that its share price is 202% more volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market.

Mineralys Therapeutics has lower revenue, but higher earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	9,299.90	-$155.20M	-$2.08	N/A
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A

Summary

Mineralys Therapeutics beats Spyre Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Mineralys Therapeutics compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Mineralys Therapeutics (NASDAQ:MLYS) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

In the previous week, Mineralys Therapeutics had 1 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 8 mentions for Mineralys Therapeutics and 7 mentions for Crinetics Pharmaceuticals. Mineralys Therapeutics' average media sentiment score of 1.03 beat Crinetics Pharmaceuticals' score of 0.19 indicating that Mineralys Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crinetics Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mineralys Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mineralys Therapeutics has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. Mineralys Therapeutics' return on equity of -27.92% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%
Mineralys Therapeutics	N/A	-27.92%	-26.98%

Mineralys Therapeutics has lower revenue, but higher earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$7.70M	1,149.02	-$465.32M	-$5.13	N/A
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A

Crinetics Pharmaceuticals has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market.

Crinetics Pharmaceuticals presently has a consensus price target of $78.27, suggesting a potential downside of 6.72%. Mineralys Therapeutics has a consensus price target of $49.33, suggesting a potential upside of 82.18%. Given Mineralys Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Mineralys Therapeutics is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	10 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.29
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are held by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are held by insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Mineralys Therapeutics beats Crinetics Pharmaceuticals on 12 of the 14 factors compared between the two stocks.

How does Mineralys Therapeutics compare to Qiagen?

Qiagen (NYSE:QGEN) and Mineralys Therapeutics (NASDAQ:MLYS) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

In the previous week, Qiagen had 3 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 11 mentions for Qiagen and 8 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.03 beat Qiagen's score of 0.86 indicating that Mineralys Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	6 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mineralys Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Qiagen has a net margin of 19.16% compared to Mineralys Therapeutics' net margin of 0.00%. Qiagen's return on equity of 14.40% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
Mineralys Therapeutics	N/A	-27.92%	-26.98%

Qiagen has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	4.09	$424.88M	$1.91	21.73
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A

Qiagen currently has a consensus price target of $43.34, indicating a potential upside of 4.42%. Mineralys Therapeutics has a consensus price target of $49.33, indicating a potential upside of 82.18%. Given Mineralys Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Mineralys Therapeutics is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	1 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.36
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

70.0% of Qiagen shares are held by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are held by institutional investors. 9.0% of Qiagen shares are held by insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Qiagen has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market.

Summary

Qiagen beats Mineralys Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Mineralys Therapeutics compare to TG Therapeutics?

Mineralys Therapeutics (NASDAQ:MLYS) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

TG Therapeutics has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A
TG Therapeutics	$616.29M	13.64	$447.18M	$2.86	19.21

84.5% of Mineralys Therapeutics shares are held by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are held by institutional investors. 18.9% of Mineralys Therapeutics shares are held by company insiders. Comparatively, 8.9% of TG Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, TG Therapeutics had 11 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 19 mentions for TG Therapeutics and 8 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.03 beat TG Therapeutics' score of 0.48 indicating that Mineralys Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mineralys Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mineralys Therapeutics presently has a consensus price target of $49.33, suggesting a potential upside of 82.18%. TG Therapeutics has a consensus price target of $53.33, suggesting a potential downside of 2.91%. Given Mineralys Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Mineralys Therapeutics is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

Mineralys Therapeutics has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.6, indicating that its stock price is 60% more volatile than the broader market.

TG Therapeutics has a net margin of 65.95% compared to Mineralys Therapeutics' net margin of 0.00%. TG Therapeutics' return on equity of 88.73% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mineralys Therapeutics	N/A	-27.92%	-26.98%
TG Therapeutics	65.95%	88.73%	43.44%

Summary

TG Therapeutics beats Mineralys Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Mineralys Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MLYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MLYS vs. The Competition

Export

Metric	Mineralys Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.25B	$3.67B	$6.96B	$12.67B
Dividend Yield	N/A	2.20%	2.68%	8.87%
P/E Ratio	-13.21	21.07	27.19	24.06
Price / Sales	N/A	300.81	574.55	112.08
Price / Cash	N/A	146.26	49.25	59.89
Price / Book	3.31	8.39	10.85	6.23
Net Income	-$154.65M	$23.83M	$3.59B	$331.94M
7 Day Performance	-4.58%	-3.70%	-1.94%	-1.66%
1 Month Performance	7.76%	3.04%	2.20%	-1.03%
1 Year Performance	88.84%	42.73%	23.81%	17.09%

Mineralys Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MLYS Mineralys Therapeutics	3.1511 of 5 stars	$26.96 -0.4%	$49.33 +83.0%	+89.1%	$2.21B	N/A	N/A	28	Positive News
PRAX Praxis Precision Medicines	3.2983 of 5 stars	$322.20 +2.4%	$563.50 +74.9%	+474.7%	$8.98B	$8.55M	N/A	110
SYRE Spyre Therapeutics	1.7949 of 5 stars	$101.83 +8.6%	$101.42 -0.4%	+481.0%	$8.95B	$890K	N/A	73
CRNX Crinetics Pharmaceuticals	1.444 of 5 stars	$83.74 +0.1%	$78.27 -6.5%	+163.0%	$8.83B	$7.70M	N/A	210
QGEN Qiagen	4.0076 of 5 stars	$41.66 +0.5%	$43.34 +4.0%	-18.4%	$8.58B	$2.09B	21.75	5,654	Positive News Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MLYS) was last updated on 7/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mineralys Therapeutics (MLYS) Competitors

MLYS vs. PRAX, SYRE, CRNX, QGEN, and TGTX

How does Mineralys Therapeutics compare to Praxis Precision Medicines?

Summary

How does Mineralys Therapeutics compare to Spyre Therapeutics?

Summary

How does Mineralys Therapeutics compare to Crinetics Pharmaceuticals?

Summary

How does Mineralys Therapeutics compare to Qiagen?

Summary

How does Mineralys Therapeutics compare to TG Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLYS vs. The Competition

Mineralys Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mineralys Therapeutics (MLYS) Competitors

MLYS vs. PRAX, SYRE, CRNX, QGEN, and TGTX

How does Mineralys Therapeutics compare to Praxis Precision Medicines?

Is PRAX or MLYS more profitable?

Does the media prefer PRAX or MLYS?

Which has stronger earnings & valuation, PRAX or MLYS?

Do insiders & institutionals hold more shares of PRAX or MLYS?

Do analysts recommend PRAX or MLYS?

Which has more risk & volatility, PRAX or MLYS?

Summary

How does Mineralys Therapeutics compare to Spyre Therapeutics?

Do analysts recommend SYRE or MLYS?

Does the media prefer SYRE or MLYS?

Is SYRE or MLYS more profitable?

Do insiders and institutionals hold more shares of SYRE or MLYS?

Which has more volatility & risk, SYRE or MLYS?

Which has better valuation & earnings, SYRE or MLYS?

Summary

How does Mineralys Therapeutics compare to Crinetics Pharmaceuticals?

Does the media prefer CRNX or MLYS?

Is CRNX or MLYS more profitable?

Which has higher valuation and earnings, CRNX or MLYS?

Which has more volatility and risk, CRNX or MLYS?

Do analysts recommend CRNX or MLYS?

Do institutionals & insiders hold more shares of CRNX or MLYS?

Summary

How does Mineralys Therapeutics compare to Qiagen?

Does the media prefer QGEN or MLYS?

Is QGEN or MLYS more profitable?

Which has better valuation and earnings, QGEN or MLYS?

Do analysts rate QGEN or MLYS?

Do insiders & institutionals believe in QGEN or MLYS?

Which has more risk and volatility, QGEN or MLYS?

Summary

How does Mineralys Therapeutics compare to TG Therapeutics?

Which has better earnings and valuation, MLYS or TGTX?

Do institutionals & insiders have more ownership in MLYS or TGTX?

Does the media refer more to MLYS or TGTX?

Do analysts rate MLYS or TGTX?

Which has more risk & volatility, MLYS or TGTX?

Is MLYS or TGTX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLYS vs. The Competition

Mineralys Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools